Strides Pharma Science Ltd.
Fundamentals
- Market cap
- ₹9,975 cr
- P/E
- 17.93×
- ROE
- 140.82%
- Debt / equity
- 0.70
- Div yield
- 0.45%
- 52-week range
- 768.65 — 1231.00
Company snapshot
Strides Pharma Science Ltd.
Pharmaceuticals
₹10,628 cr
P/E 19.11×
Latest quarter · Mar 2026
Sales₹1,323 cr
Net profit₹128 cr
Op. margin+18.1%
EPS₹13.77
Strength & growth
Debt / equity0.70×
Current ratio1.20×
Sales CAGR+4.5%
EPS CAGR+16.4%
The timeline — 2 notes on Strides Pharma Science Ltd.
May 2026
- 21 May 26 · 1:55 PM IST Brief Brief · Earnings · Mid cap
Strides Pharma Q4 transcript: nothing new from May 18 call
The earnings call transcript filed today reiterates the US revenue aspiration of $375-400M and strong ex-US growth, all of which were shared during the live call and in the subsequent summary.
- 20 May 26 · 10:03 PM IST Brief Brief · Mid cap
Strides Pharma's flagship plant draws 5 FDA observations
A Form 483 at the company's main manufacturing site raises the stakes for a warning letter or import ban. Response due in 15 days.